It is no surprise that cardiovascular outcomes are most commonly reported, given the increased likelihood of cardiovascular morbidity in AGHD, although in general, the administration of GH replacement therapy appears to positively impact the prognosis of cardiovascular diseases in these patients, with more recent sex differences noted [1, 51]. The gene discussed is GH1; the disease is cardiovascular disorder.